{"id":10619,"date":"2026-04-27T10:24:37","date_gmt":"2026-04-27T14:24:37","guid":{"rendered":"https:\/\/www.curingheartdisease.com\/?p=10619"},"modified":"2026-08-25T09:08:40","modified_gmt":"2026-08-25T13:08:40","slug":"es-la-enfermedad-cardiaca-una-eleccion-el-secreto-de-riesgo-cero-para-detener-la-placa","status":"publish","type":"post","link":"https:\/\/www.curingheartdisease.com\/es\/is-heart-disease-a-choice-the-zero-risk-secret-to-stopping-plaque\/","title":{"rendered":"\u00bfEs la cardiopat\u00eda una elecci\u00f3n? El secreto del \u2018riesgo cero\u2019 para detener la placa"},"content":{"rendered":"

Is Atherosclerosis Biologically Eliminated at Ultra-Low Lifelong LDL Levels?<\/h2>\n

A Critical Evaluation of the \u201cZero-Risk\u201d Hypothesis<\/em><\/h3>\n

Atherosclerotic cardiovascular disease (ASCVD) has long been framed as an inevitable consequence of human senescence, yet contemporary molecular biology and genetic epidemiology increasingly converge on a substrate-dependent model in which the disease is, in principle, biologically avoidable [1], [2]. The premise of the \u201czero-risk\u201d hypothesis is that atherosclerosis is primarily an apolipoprotein B (ApoB)\u2013driven disorder [2], [3]. By maintaining lifelong exposure to ultra-low levels of low-density lipoprotein cholesterol (LDL-C) and its corresponding ApoB particle concentration\u2014approximately 10\u201320 mg\/dL (0.26\u20130.52 mmol\/L), near the physiological newborn baseline\u2014the probability of initiating the pathognomonic lesion of atherosclerosis (subendothelial retention of atherogenic lipoproteins) may be reduced to a level that is biologically negligible [2], [4]. This report evaluates whether such ultra-low exposure effectively eliminates disease initiation, or whether residual pathways involving inflammation, lipoprotein(a) [Lp(a)], and endothelial dysfunction retain the capacity to seed arterial plaque independently of ApoB [5], [6].<\/p>\n

\"\"<\/p>\n

The Response-to-Retention Model: A Deterministic Framework for Initiation<\/h3>\n

The theoretical basis for the biological elimination of atherosclerosis rests on the response-to-retention hypothesis, which identifies subendothelial trapping of ApoB-containing lipoproteins as the necessary and sufficient initiating event for atherogenesis [1], [7]. While traditional models emphasized frank endothelial injury as the primary trigger, current evidence indicates that an intact, though dysfunctional, endothelium typically overlies early and intermediate lesions [1], [8]. Disease initiation occurs when lipoproteins smaller than approximately 70 nm in diameter\u2014including LDL, triglyceride-rich remnants, and Lp(a)\u2014traverse the endothelial barrier and enter the tunica intima [2], [7].<\/p>\n

Molecular Interactions within the Intimal Matrix<\/h4>\n

Within the intima, retained particles interact with the extracellular matrix (ECM), particularly with negatively charged proteoglycans such as versican, perlecan, biglycan, and decorin [1], [7]. Positively charged regions of ApoB, specifically sequences rich in lysine and arginine residues, bind electrostatically to the glycosaminoglycan (GAG) chains of these proteoglycans [1]. This is not passive entrapment; it is a critical biochemical event that prolongs the residence time of the lipoprotein within the arterial wall by an order of magnitude relative to plasma transit [9].<\/p>\n\n\n\n\n\n\n\n\n
Proteoglycan<\/strong><\/td>\nInteraction with ApoB Lipoproteins<\/strong><\/td>\nRole in Atherogenesis<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Versican<\/td>\nLarge aggregating proteoglycan that expands intimal volume<\/td>\nPromotes lipoprotein trapping and smooth muscle cell migration [7]<\/td>\n<\/tr>\n
Perlecan<\/td>\nBasement-membrane heparan sulfate proteoglycan<\/td>\nStructural scaffold facilitating early particle retention [7]<\/td>\n<\/tr>\n
Biglycan<\/td>\nSmall leucine-rich proteoglycan with high ApoB affinity<\/td>\nCorrelates with development of lipid-rich necrotic core [7]<\/td>\n<\/tr>\n
Decorin<\/td>\nInteracts with collagen and LDL particles<\/td>\nModulates fibrotic response and lipoprotein aggregation [7]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Prolonged intimal residence renders retained lipoproteins highly susceptible to chemical modification, including oxidation, glycation, enzymatic cleavage, and aggregation [1], [9]. Modified particles trigger a maladaptive immune response [1], [7]. Endothelial cells activated by modified lipids and mechanical stressors express adhesion molecules (VCAM-1, ICAM-1) and secrete chemokines that recruit monocytes into the subendothelial space [1], [10]. These monocytes differentiate into macrophages that internalize modified lipoproteins via scavenger receptors and transform into lipid-laden foam cells\u2014the morphological hallmark of the fatty streak [10].<\/p>\n

Thermodynamic and Kinetic Limits of Retention<\/h4>\n

The probability of particle retention is a function of the local concentration of ApoB particles and the availability of proteoglycan binding sites within the matrix [7]. In a stochastic model of the arterial wall, the rate of lipid accumulation is determined by the flux of lipoproteins into the intima and the kinetics of proteoglycan binding [9]. At ultra-low circulating concentrations (e.g., LDL-C \u2248 15 mg\/dL), the number of particles available for transcytosis is vastly reduced [2], [11].<\/p>\n

If the rate of particle entry is low enough that the arterial wall\u2019s endogenous clearance mechanisms\u2014macrophage-mediated phagocytosis and HDL-mediated reverse cholesterol transport\u2014can remove particles before pro-inflammatory modification, the inflammatory cascade is never initiated [1], [12]. This is the mechanistic basis for a biological \u201cno-effect\u201d threshold for ApoB concentration, below which the probability of initiating a lesion approaches zero [7].<\/p>\n

The Quantitative Relationship of Cumulative Exposure: Plaque-Years<\/h3>\n

Clinical risk of ASCVD reflects not instantaneous LDL-C but the integral of exposure over time, a concept now formalized as \u201ccumulative LDL exposure\u201d or \u201cplaque-years\u201d [13], [14]. Under this framework, atherosclerosis is a disease of gradual substrate accumulation, and the time to a clinical event is determined by how quickly an individual crosses a personal plaque threshold [13]. Domanski and colleagues formally demonstrated in a pooled analysis of 4,958 participants from ARIC, CARDIA, MESA, and the Framingham Offspring Study that the cumulative burden of LDL-C exposure, the time course of that exposure, and the slope of LDL-C change over time each independently predicted incident cardiovascular events [14].<\/p>\n

Defining the Plaque-Year Thresholds<\/h4>\n

Analysis of epidemiologic and Mendelian randomization data permits tentative quantification of cumulative-exposure thresholds [13], [15]. Published thresholds remain approximate and cohort-dependent rather than formally validated across populations, and the values below are best regarded as heuristic estimates drawn from long-term cohort and Mendelian randomization data [13]\u2013[15].<\/p>\n\n\n\n\n\n\n\n\n
Risk Metric (Men)<\/strong><\/td>\nApprox. Cumulative LDL Exposure (g\u00b7yr\/dL)<\/strong><\/td>\nLifetime Major Event Risk (approx.)<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Low-Risk Threshold<\/td>\n~ 5,000<\/td>\n< 10% probability of event [13], [14]<\/td>\n<\/tr>\n
Intermediate Threshold<\/td>\n~ 8,000<\/td>\nApproximate median age for non-zero CAC (~age 55\u201360) [13], [16]<\/td>\n<\/tr>\n
High-Risk Threshold<\/td>\n~ 11,000<\/td>\n>20% probability of event [13], [14]<\/td>\n<\/tr>\n
Very High-Risk Threshold<\/td>\n~ 14,000<\/td>\nApproximate median age for CAC \u2265 100 [13], [16]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Note: <\/strong>Thresholds for women are generally higher (estimated by roughly 20\u201330% at comparable risk strata), consistent with the observed later-life onset of ASCVD in women and premenopausal attenuation of LDL transcytosis and arterial-wall biology [13].<\/p>\n

Influence of Secondary Risk Factors on the Retention Threshold<\/h4>\n

Cumulative LDL exposure required to initiate events is not static; it is modulated by the biological environment of the artery [13]. Hypertension, diabetes, and smoking effectively lower the threshold by increasing particle retention or accelerating inflammatory response to retained lipids [2], [17].<\/p>\n